Yeah, their CRO (?). But I don't see the rationale
Post# of 145351
![Avatar](/images/ProfileImages/167738657_59587_mando klein.jpg)
As trding wrote some time ago:
Quote:
Is leronlimab a breakthrough? Well the first possible mono approval, no developed resistance in 830 patients, combo trial with twice the efficacy of past approvals. No SAEs in 15 years. Better safety, better efficacy, lower toxicity, no resistance development. Longer half-life, with once a week dosing. Many of these patient developed resistance by skipping doses, they would allow them to be covered if they forget to take their pills a couple days.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)